Minerva Neurosciences | NERV - Assets


Minerva Neurosciences reported $97.97M in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Adma Biologics USD 624.24M 55.56M Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
BioCryst Pharmaceuticals USD 514.16M 67.73M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Cipla INR 401.64B 27.77B Sep/2025
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 156.57M 58.73M Dec/2025
CSL USD 37.9B 1.5B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Esperion Therapeutics USD 465.89M 101.87M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 2.53B 304.09M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
J&J USD 199.21B 6.39B Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Minerva Neurosciences USD 97.97M 69.88M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 110.95B 3.66B Dec/2025
Novavax USD 1.18B 3.38M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Takeda JPY 15.41T 938.47B Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025